10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-TNFRSF5 / CD40 Reference Antibody (selicrelumab)

Recombinant Antibody
Catalog # APR10095

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P25942
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG2
Calculated MW	30619

Additional Information


Target/Specificity	TNFRSF5 / CD40
Endotoxin	
Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.


Protein Information

Name	CD40
Synonyms	TNFRSF5
Function	Receptor for TNFSF5/CD40LG (PubMed: 31331973). Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion (By similarity).
Cellular Location	[Isoform I]: Cell membrane; Single-pass type I membrane protein
Tissue Location	B-cells and in primary carcinomas.


Images

Anti- Human CD40(Selicrelumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.







The purity of anti- Human CD40(Selicrelumab) is more than 95%, determined by SEC-HPLC.




Immobilized human CD40 (His Tag, 2 μg/mL) can bind to anti- Human CD40(Selicrelumab) with an EC50 of 0.009782 ug/mL.



Anti-human CD40(Selicrelumab) inhibited the tumor growth of MC38 on humanized CD40 mice. The result showed significant anti-tumor effects.




Compared with the negative control group, anti- human CD40(Selicrelumab) had a significant increase in visceral ratio at a dose of 20 MPk and no significant difference at a dose of 1 mpk, indicating that the toxicity of selicrelumab to the spleen was significantly dose-dependent.



Compared with the negative control group, anti- human CD40(Selicrelumab)had a significant increase in serum ALT content at a dose of 20 mpk, and a trend of increase in serum ALT at a dose of 1 mpk, but there was no statistical difference. AST indexes were all elevated and dose-dependent, but there was no statistical difference.

Compared with the negative control group, anti- human CD40(Selicrelumab) had a significant increase in serum ALT content at a dose of 20 mpk, and a trend of increase



in serum ALT at a dose of 1 mpk, but there was no statistical difference. AST indexes were all elevated and dose-dependent, but there was no statistical difference.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.